Kopp Family Office LLC Acquires Shares of 34,540 CeriBell, Inc. $CBLL

Kopp Family Office LLC bought a new stake in CeriBell, Inc. (NASDAQ:CBLL) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 34,540 shares of the company’s stock, valued at approximately $672,000. CeriBell accounts for 0.4% of Kopp Family Office LLC’s investment portfolio, making the stock its 20th biggest holding.

Several other hedge funds have also recently modified their holdings of CBLL. Strs Ohio purchased a new position in CeriBell in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the 3rd quarter worth approximately $33,000. CWM LLC increased its stake in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter.

Insider Activity

In other news, Director Joseph Michael Taylor sold 5,500 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00. Following the transaction, the director owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. The trade was a 8.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00. Following the completion of the sale, the chief executive officer directly owned 802,317 shares of the company’s stock, valued at $15,966,108.30. This represents a 4.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 300,685 shares of company stock worth $5,935,326. Insiders own 17.70% of the company’s stock.

Analysts Set New Price Targets

CBLL has been the topic of a number of research analyst reports. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Canaccord Genuity Group decreased their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.20.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: FDA clearance strengthens the product offering. CeriBell received 510(k) clearance for two AI enhancements to its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The features are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and interpret recordings more efficiently in emergency and intensive-care settings. The upgrades require no installation downtime and could improve the clinical utility and adoption of CeriBell’s point-of-care monitoring system. CeriBell FDA clearance announcement
• Positive Sentiment: Quarterly revenue exceeded expectations. CeriBell reported second-quarter revenue of $28.1 million, above the roughly $27.3 million analyst consensus. The company also issued full-year 2026 revenue guidance of $114 million to $117 million, with the midpoint modestly above consensus expectations of $114 million. CeriBell second-quarter 2026 results
• Neutral Sentiment: Institutional interest is mixed. Recent filings show more institutions added CeriBell shares than reduced positions, including sizable additions by FMR, Adage Capital and Millennium Management. However, other investors also trimmed holdings, so the data does not provide a clear near-term signal.
• Negative Sentiment: The quarterly loss was wider than expected and increased year over year. CeriBell reported a loss of $0.51 per share, compared with analyst estimates ranging from $0.45 to $0.47 and a $0.38 loss in the year-ago quarter. The company continues to post substantial losses, including a negative net margin, which may limit enthusiasm despite revenue growth. CeriBell second-quarter earnings analysis
• Negative Sentiment: Insider selling could weigh on sentiment. Reported insider activity over the past six months included numerous sales and no open-market purchases, including selling by senior executives. While such transactions may reflect personal liquidity needs, the absence of insider buying is a potentially cautious signal for investors.

CeriBell Price Performance

NASDAQ:CBLL opened at $19.30 on Tuesday. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The stock has a market cap of $732.24 million, a PE ratio of -11.84 and a beta of 0.81. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The stock has a 50 day moving average price of $18.55 and a 200 day moving average price of $19.08.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Equities research analysts expect that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.